Eric J Roeland
Overview
Explore the profile of Eric J Roeland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Braun I, Bohlke K, Roeland E
JCO Oncol Pract
. 2024 Mar;
20(6):767-770.
PMID: 38478793
@JCO_ASCO guideline on #cannabis in cancer with @JCOOP_ASCO companion Q&A addressing key clinical questions.
12.
Braun I, Bohlke K, Abrams D, Anderson H, Balneaves L, Bar-Sela G, et al.
J Clin Oncol
. 2024 Mar;
42(13):1575-1593.
PMID: 38478773
Purpose: To guide clinicians, adults with cancer, caregivers, researchers, and oncology institutions on the medical use of cannabis and cannabinoids, including synthetic cannabinoids and herbal cannabis derivatives; single, purified cannabinoids;...
13.
Roeland E, Fintelmann F, Hilton F, Yang R, Whalen E, Tarasenko L, et al.
J Cachexia Sarcopenia Muscle
. 2024 Mar;
15(3):1030-1040.
PMID: 38468440
Background: This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy....
14.
Jarnagin J, Saraf A, Baiev I, Chi G, Van Seventer E, Mojtahed A, et al.
JAMA Netw Open
. 2023 Nov;
6(11):e2343512.
PMID: 37976066
Importance: Patient-reported outcomes (PROs), such as quality of life (QOL) and symptoms, are often associated with clinical outcomes in patients with cancer. In practice, oncologists use serum tumor markers (TMs)...
15.
Winters-Stone K, Krasnow S, Horak F, Mancini M, Cameron M, Dieckmann N, et al.
BMC Cancer
. 2023 Nov;
23(1):1087.
PMID: 37946117
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting side effect of systemic cancer therapy. In many cancer survivors, CIPN persists after treatment ends and is associated with functional...
16.
Winters-Stone K, Stoyles S, Dieckmann N, Eckstrom E, Luoh S, Horak F, et al.
Res Sq
. 2023 Oct;
PMID: 37886571
Purpose: To determine whether strength training or tai ji quan can reduce frailty in older, postmenopausal women treated with chemotherapy for cancer. Methods: We conducted a secondary data analysis from...
17.
Schwartzberg L, Navari R, Ruddy K, LeBlanc T, Clark-Snow R, Wickham R, et al.
Support Care Cancer
. 2023 Oct;
31(12):654.
PMID: 37878086
Purpose: Chemotherapy-induced nausea and vomiting (CINV)'s impact on work loss remains poorly described. We evaluated associations between the duration of CINV episodes, CINV-related work loss (CINV-WL), and CINV-related activity impairment...
18.
Saraf A, Tahir I, Hu B, Dietrich A, Tonnesen P, Sharp G, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jul;
118(1):94-103.
PMID: 37506979
Purpose: Sarcopenia, an age-related decline in muscle mass and physical function, is associated with increased toxicity and worse outcomes in women with breast cancer (BC). Sarcopenia may contribute to toxicity-related...
19.
Roeland E, Bohlke K, Baracos V, Smith T, Loprinzi C
J Clin Oncol
. 2023 Jul;
41(25):4178-4179.
PMID: 37467399
20.
Winters-Stone K, Roeland E, Li F, Eckstrom E, Horak F, Dieckmann N, et al.
J Clin Oncol
. 2023 Jun;
41(26):4316-4317.
PMID: 37379504
No abstract available.